Evidence map›Paper›PMID 41821763›Full record

ArticleNeuro-oncology advances

Treatment initiation by positive liquid biopsy alone in primary central nervous system lymphoma: A retrospective analysis of a multi-institutional study.

Masaki Mitobe, Satoshi Shibuma, Haruhiko Takahashi, Jotaro On, Toru Takino, Keita Kawabe, Yoshihiro Mouri, Shunsuke Kumagai, Takashi Kozakai, Akihito Momoi and 21 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Masaki MitobeDepartment of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan.
Satoshi ShibumaDepartment of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan.
Haruhiko TakahashiDepartment of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan.
Jotaro OnDepartment of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan.
Toru TakinoDepartment of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan.
Keita KawabeDepartment of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan.
Yoshihiro MouriDepartment of Neurosurgery, Niigata Prefectural Central Hospital, Joetsu, Japan.
Shunsuke KumagaiDepartment of Neurosurgery, Niigata Prefectural Central Hospital, Joetsu, Japan.
Takashi KozakaiDepartment of Hematology, Niigata Prefectural Central Hospital, Joetsu, Japan.
Akihito MomoiDepartment of Hematology, Niigata Prefectural Central Hospital, Joetsu, Japan.
Naomi SuzukiDepartment of Neurology, Niigata Prefectural Shibata Hospital, Shibata, Japan.
Takao FukushimaDepartment of Neurology, Niigata Prefectural Shibata Hospital, Shibata, Japan.
Takaharu SuzukiDepartment of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan.
Hiroyuki KurodaDepartment of Hematology, Niigata Prefectural Shibata Hospital, Shibata, Japan.
Etsuji SajiDepartment of Neurology, Niigata City General Hospital, Niigata, Japan.
Kimihiko NakamuraDepartment of Neurosurgery, Niigata City General Hospital, Niigata, Japan.
Hideki HashidateDepartment of Pathology, Niigata City General Hospital, Niigata, Japan.
Asa NakaharaDepartment of Pathology, Brain Research Institute, Niigata University, Niigata, Japan.
Takahiro TomitaDepartment of Neurosurgery, Graduate School of Medicine and Pharmaceutical Science, University of Toyama, Toyama, Japan.
Jun WatanabeDepartment of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan.
Yoshihiro TsukamotoDepartment of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan.
Masayasu OkadaDepartment of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan.
Tetsuya HiraishiDepartment of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan.
Shinya YamashitaDepartment of Neurosurgery, Niigata Prefectural Central Hospital, Joetsu, Japan.
Takuya AkaiDepartment of Neurosurgery, Graduate School of Medicine and Pharmaceutical Science, University of Toyama, Toyama, Japan.
Satoshi KurodaDepartment of Neurosurgery, Graduate School of Medicine and Pharmaceutical Science, University of Toyama, Toyama, Japan.
Akiyoshi KakitaDepartment of Pathology, Brain Research Institute, Niigata University, Niigata, Japan.ORCID https://orcid.org/0000-0003-4244-0277
Hirohito SoneDepartment of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan.ORCID https://orcid.org/0000-0003-1263-2817
Jun TakizawaDepartment of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan.
Makoto OishiDepartment of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan.
Manabu NatsumedaDepartment of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan.ORCID https://orcid.org/0000-0003-3098-8323

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The gold standard for the diagnosis of primary central nervous system lymphoma (PCNSL) remains surgical biopsy, but it carries the risk of complications, and operability depends on the size and location of the lesion or the patient's condition. Previously, we have reported the reliable detection of Methods: We analyzed 10 patients from 5 institutions who were deemed difficult to biopsy surgically and were subsequently treated based on the detection of Results: Surgical biopsy was not performed in 8 patients because the lesions were located in deep locations, such as the brainstem, and in 2 patients because of low performance status and/or advanced age. Conclusions: Liquid biopsy for the diagnosis of PCNSL has the potential to replace surgical biopsy with a less-invasive method and early diagnosis, leading to early treatment and possibly better outcomes. Further large-scale studies are warranted to establish the reliability of this approach.

Indexed as

diagnosisdroplet digital PCRliquid biopsyMYD88 L265Pprimary central nervous system lymphoma

Identifiers

PMID41821763
PMCPMC12978307

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.